Researchers at the University of Michigan have had initial success in mice using nanodiscs to deliver a customized therapeutic vaccine for the treatment of colon and melanoma cancer tumors.
“We are basically educating the immune system with these nanodiscs so that immune cells can attack cancer cells in a personalized manner,” said James Moon, the John Gideon Searle assistant professor of pharmaceutical sciences and biomedical engineering.
Personalized immunotherapy is a fast-growing field of research in the fight against cancer.
The therapeutic cancer vaccine employs nanodiscs loaded with tumor neoantigens, which are unique mutations found in tumor cells. By generating T-cells that recognize these specific neoantigens, the technology targets cancer mutations and fights to eliminate cancer cells and prevent tumor growth.
Unlike preventive vaccinations, therapeutic cancer vaccines of this type are meant to kill established cancer cells.
“The idea is that these vaccine nanodiscs will trigger the immune system to fight the existing cancer cells in a personalized manner,” Moon said.
The nanodisc technology was tested in mice with established melanoma and colon cancer tumors. After the vaccination, twenty-seven percent of T-cells in the blood of the mice in the study targeted the tumors.
When combined with immune checkpoint inhibitors, an existing technology that amplifies T-cell tumor-fighting responses, the nanodisc technology killed tumors within 10 days of treatment in the majority of the mice. After waiting 70 days, researchers then injected the same mice with the same tumor cells, and the tumors were rejected by the immune system and did not grow.
“This suggests the immune system ‘remembered’ the cancer cells for long-term immunity,” said Rui Kuai, U-M doctoral student in pharmaceutical sciences and lead author of the study.
“The holy grail in cancer immunotherapy is to eradicate tumors and prevent future recurrence without systemic toxicity, and our studies have produced very promising results in mice,” Moon said.
The technology is made of extremely small, synthetic high density lipoproteins measuring roughly 10 nanometers. By comparison, a human hair is 80,000 to 100,000 nanometers wide.
“It’s a powerful vaccine technology that efficiently delivers vaccine components to the right cells in the right tissues. Better delivery translates to better T-cell responses and better efficacy,” said study co-senior author Anna Schwendeman, U-M assistant professor of pharmacy.
The next step is to test the nanodisc technology in a larger group of larger animals, Moon said.
Learn more: Nanodiscs deliver personalized cancer therapy to immune system
[osd_subscribe categories=’personalized-immunotherapy’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “PERSONALIZED IMMUNOTHERAPY”‘]
Receive an email update when we add a new PERSONALIZED IMMUNOTHERAPY article.
The Latest on: Personalized immunotherapy
[google_news title=”” keyword=”personalized immunotherapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Personalized immunotherapy
- Developing a Personalized Vaccine Against Cancerous Brain Tumorson May 10, 2024 at 1:05 am
Pairing a personalized dendritic cell vaccine with an immune-boosting compound improves the immune response to malignant gliomas.
- AI-driven model identifies potent cancer-killing immune cells for personalized immunotherapyon May 7, 2024 at 9:46 pm
Using artificial intelligence, Ludwig Cancer Research scientists have developed a powerful predictive model for identifying the most potent cancer killing immune cells for use in cancer ...
- New mRNA cancer vaccine helps immune system fight deadly brain tumorson May 7, 2024 at 8:23 am
Researchers from the University of Florida have developed a new mRNA cancer vaccine to retrain the body's immune system to attack and potentially treat glioblastoma, a deadly form of brain cancer.
- FDA approves new immunotherapy treatment for melanomaon May 6, 2024 at 5:45 pm
Melanoma is considered the deadliest of all skin cancers. Now the FDA has approved an immunotherapy treatment that could help extend lives. The single-dose immunotherapy is currently approved for ...
- Larysa Baraban receives professorship for Medical Nanotechnology at TUD Dresden University of Technologyon May 6, 2024 at 4:59 pm
Prof. Larysa Baraban took up the newly created Chair of Medical Nanotechnology at the Faculty of Medicine Carl Gustav Carus at TUD Dresden University of Technology on 1 May 2024. The professorship was ...
- New gene signature could transform immunotherapy for gastrointestinal cancerson April 30, 2024 at 1:31 pm
Despite significant progress in treating gastrointestinal (GI) cancers through surgical resection, chemotherapy, radiotherapy, and targeted therapy, the objective response rate (ORR) for immune ...
- Breaking: AI Could Transform Cancer Treatment by Predicting Immunotherapy Successon April 30, 2024 at 8:27 am
In this article, we’ll explore a breakthrough development in the fight against cancer: how artificial intelligence (AI) is poised to predict immunotherapy success. This has the potential to ...
- Can cancer vaccine with immunotherapy shrink liver tumor?on April 26, 2024 at 7:30 pm
According to a study published in the journal Nature Medicine, people with Hepatocellular Carcinoma treated with immunotherapy and a personalized anti-tumor vaccine were twice as likely to experience ...
- U.K. Tests World-First Personalized Skin Cancer Vaccineon April 26, 2024 at 9:08 am
Customized with genetic information from a patient’s own tumor, vaccines like this could one day be used against lung, kidney, bladder and colon cancer.
via Bing News